Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Califf Supports Combo Products Pathway At Confirmation Hearing

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's concepts for new pathway could be ready for congressional scrutiny within a year.

You may also be interested in...



Combo Products Won't Get Special Review Pathway At US FDA Anytime Soon

Jeffrey Shuren and Janet Woodcock tell Senate committee that agency is more concerned with implementing combination product provisions of the 21st Century Cures Act.

FDA-Industry Relations Faulted As 'Revolving Door' In BMJ Report

Academic authors say that more than half of FDA medical reviewers leave to either work or consult to industry; experts chime in with mixed reactions to the findings.

FDA's Combo Products Review Transformation Begins

Pilot project sets timelines for lead and consulting centers that will feed into more substantial changes in PDUFA VI.

Related Content

Topics

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel